Vir’s hepatitis D drug combination succeeds in first Phase 3 study

Vir Biotechnology said its experimental combination of elebsiran and tobevibart succeeded in the first of three Phase 3 studies for chronic hepatitis D. After 48 weeks, 44% of participants receiving the treatment met the main study objective, which involved largely eliminating detectable signs of the virus and normalizing levels of a liver enzyme. None of the participants in a delayed-treatment group achieved those results, according to Vir.

The combination also met a secondary objective focused on reducing viral levels, with 79% of treated participants achieving a treatment response. Two other Phase 3 trials are ongoing, and Vir expects data early next year. If results from all three studies are positive, the company said they would support a regulatory submission in 2027.